Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Just For You 3 Stocks Under $5 With Strong Analyst Upside PotentialBy Chris Markoch. First Published: 2/24/2026. 
Key Points - Grab Holdings is gaining analyst support as revenue growth and its first full year of profitability highlight long-term opportunity in Southeast Asia’s expanding digital economy.
- Vaxart offers speculative biotech upside with its oral vaccine platform targeting influenza, norovirus, and COVID-19, creating a high-risk, high-reward setup.
- ThredUp is positioned to benefit from the fast-growing resale market, with strong institutional ownership and industry forecasts pointing to sustained secondhand demand.
- Special Report: [Sponsorship-Ad-6-Format3]
While many investors are rotating out of speculative penny stocks, others still embrace the risk-reward tradeoff. Stocks that trade under $5 typically carry higher risk: many of these companies are unprofitable and some generate little to no revenue. These names are also generally small-cap companies, and small caps have been beaten up over the past several years. Even with pockets of strength in the Russell 2000, that recovery hasn't been broad-based across the small-cap sector. Silver: 20% + 68%
Tim Plaehn just found a Silver ETF that delivers monthly income (up to 20% in annual distributions) plus share appreciation (68% in 5 months). The precious metal has become one of the best investments for growth AND income right now. Click here and start to collect in the next 30 days. That could change in 2026 if the economic outlook continues to improve, as money may begin flowing back into more speculative names. But as with any segment of the market, quality matters. One way to filter for quality is to look for stocks that enjoy positive analyst sentiment. That's true of the three names below — each lets an investor start a sizable position with a relatively small outlay while still offering the potential for significant upside over the next five years. Profitability Milestone Meets Long-Term Emerging Market Growth Emerging-market equities are positioned to be winners in 2026, though that hasn't helped Grab Holdings Inc. (NASDAQ: GRAB), which is down roughly 15% so far this year. Based in Singapore, Grab operates a super app that blends technology, e-commerce and fintech services. One factor behind the recent pullback is its proposed merger with Indonesian ride-hailing competitor GoTo. The deal isn't finalized and could face material legislative changes in Indonesia that would limit earnings potential in that market. Grab also missed revenue expectations slightly in its Q4 2025 report. Still, revenue grew 19% year-over-year (YOY), and the period marked the company's first full-year profit. Analysts are forecasting about 120% earnings growth over the next 12 months. That helps explain the bullish sentiment. GRAB shares carry a consensus price target of $6.47, roughly 54% above the current price. High-Risk Biotech With Platform Potential Penny-stock investors often turn to the biotechnology sector for asymmetric upside. One name to watch is Vaxart Inc. (OTCMKTS: VXRT), the only company on this list that meets the classic definition of a penny stock — it trades at just over $0.60 per share at the time of writing. VXRT doesn't attract heavy analyst coverage, but the analyst who has rated it in the past 12 months gave it a Buy with a $2 price target. It's common for smaller biotech firms to fly under many analysts' radar. Vaxart is a clinical-stage company, meaning all of its candidates are still in clinical trials. The potential upside is clear: Vaxart is developing oral vaccines primarily for influenza, norovirus and COVID-19. Beyond convenience and eliminating needle-related fears, the company says its platform can induce a broader immune response that may offer wider protection (company presentation). Institutional ownership in VXRT is modest at about 18%, but in dollar terms inflows have outpaced outflows by nearly 10:1 (source). Resale Tailwinds Could Turn Today's Losses Into Tomorrow's Gains ThredUp Inc. (NASDAQ: TDUP) is down about 33% in 2026, but a wider view suggests this is more of a pullback than a collapse: TDUP is up more than 66% over the last 12 months. The recent weakness comes amid a broader selloff in unprofitable companies — though ThredUp may not be unprofitable for long. The company operates an online consignment and thrift platform that's gaining traction with Gen Z, reflected in revenue growth. In its most recent quarter, revenue rose 12.5% YOY. ThredUp cites a GlobalData 2025 market survey that projects the U.S. secondhand market's gross merchandise value will grow at a compound annual growth rate (CAGR) of 9% through 2029. Institutional investors own about 89% of TDUP shares, and buying has outpaced selling roughly 2:1 by dollar value and 3:1 by trade count (source). That said, short interest sits near 17%, which can add near-term volatility. The consensus price target from six analysts is $12.50, which would represent a gain of more than 190% from the current price.
| 
